Literature DB >> 33585698

Expression and clinical significance of CMTM1 in hepatocellular carcinoma.

Xin Song1, Shidong Zhang1, Run Tian1, Chuanjun Zheng1, Yuge Xu1, Tianxian Wang1, Chunhua Bei1, Huixia Zhang1, Xiao He1, Xiaonian Zhu1, Shengkui Tan1.   

Abstract

BACKGROUND: CKLF Like Marvel Transmembrane Domain Containing 1 (CMTM1) plays a role in breast cancer and lung cancer, but studies on the occurrence and development of CMTM1 in hepatocellular carcinoma (HCC) have not been reported.
METHODS: The Cancer Genome Atlas (TCGA) database and immunohistochemistry (IHC) were used to detect CMTM1 expression in HCC tissues. The relationship between CMTM1 expression and the clinicopathological characteristics of HCC patients was analyzed by chi-square test, and the relationship between CMTM1 expression and the prognosis of HCC patients was tested by the Kaplan-Meier model.
RESULTS: Bioinformatics analysis showed that the mRNA expression of CMTM1 was upregulated in HCC tissues, and low expression of CMTM1 is associated with longer disease-free survival in patients with HCC. Similarly, the survival time of HCC patients in CMTM1 high expression group was significantly shorter than that in CMTM1 low expression group. IHC detection indicated that CMTM1 protein was highly expressed in both HCC and adjacent non-tumor tissues, with a positive expression in 84% (63/75) of HCC tissues and 89.3% (67/75) of adjacent non-tumor tissues. Moreover, CMTM1 expression was related to family history and TNM stage of HCC patients (P < 0.05), but had no relationship with other clinicopathological characteristics. The survival analysis based on IHC results showed that the prognosis of HCC patients in CMTM1 negative group was significantly poorer than that in CMTM1 positive group (P < 0.05).
CONCLUSION: CMTM1 has a high expression in HCC tissues and is related to the prognosis of HCC patients.
© 2021 Xin Song et al., published by De Gruyter.

Entities:  

Keywords:  CMTM1; HCC; TNM stage; prognosis

Year:  2021        PMID: 33585698      PMCID: PMC7862999          DOI: 10.1515/med-2021-0221

Source DB:  PubMed          Journal:  Open Med (Wars)


  23 in total

1.  [CMTM1-v17, a new potential corepressor of androgen receptor].

Authors:  Bing Mei Zhu; Ting Li; Yu Ling Zhou; Quan Sheng Song; Lu Wang
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2007-08-18

2.  Systematic investigation of CMTM family genes suggests relevance to glioblastoma pathogenesis and CMTM1 and CMTM3 as priority targets.

Authors:  Sabit Delic; Andreas Thuy; Markus Schulze; Martin A Proescholdt; Peter Dietrich; Anja-Katrin Bosserhoff; Markus J Riemenschneider
Journal:  Genes Chromosomes Cancer       Date:  2015-04-30       Impact factor: 5.006

3.  Molecular cloning and characterization of chemokine-like factor 1 (CKLF1), a novel human cytokine with unique structure and potential chemotactic activity.

Authors:  W Han; Y Lou; J Tang; Y Zhang; Y Chen; Y Li; W Gu; J Huang; L Gui; Y Tang; F Li; Q Song; C Di; L Wang; Q Shi; R Sun; D Xia; M Rui; J Tang; D Ma
Journal:  Biochem J       Date:  2001-07-01       Impact factor: 3.857

4.  Downregulated CMTM2 Poses Potential Clinical Significance in Hepatocellular Carcinoma.

Authors:  Xuefeng Guo; Shidong Zhang; Shengkui Tan; Chunhua Bei; Huixia Zhang; Xiaonian Zhu; Xiaoqiang Qiu
Journal:  DNA Cell Biol       Date:  2020-01-28       Impact factor: 3.311

5.  Overexpression of CMTM7 inhibits cell growth and migration in liver cancer.

Authors:  Zi-Ming Huang; Peng-Ling Li; Peng Yang; Xiao-Dan Hou; Yi-Li Yang; Xin Xu; Feng Xu
Journal:  Kaohsiung J Med Sci       Date:  2019-03-23       Impact factor: 2.744

6.  Molecular cloning and characterization of chemokine-like factor super family member 1 (CKLFSF1), a novel human gene with at least 23 alternative splicing isoforms in testis tissue.

Authors:  Lu Wang; Chunxiao Wu; Ying Zheng; Xiaoyan Qiu; Li Wang; Hui Fan; Wenling Han; Bingfeng Lv; Ying Wang; Xiaohui Zhu; Mingxu Xu; Peiguo Ding; Shanhong Cheng; Yingmei Zhang; Quansheng Song; Dalong Ma
Journal:  Int J Biochem Cell Biol       Date:  2004-08       Impact factor: 5.085

7.  CMTM1_v17 is a novel potential therapeutic target in breast cancer.

Authors:  Jing Wang; Guoying Zhang; Yingmei Zhang; Yang Luo; Quansheng Song; Xiaoyan Qiu; Xiaoning Mo; Lu Wang
Journal:  Oncol Rep       Date:  2014-08-20       Impact factor: 3.906

8.  Distinct expression of chemokine-like factor 1 in synovium of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.

Authors:  Ke Tao; Xu Tang; Bin Wang; Ru-Jun Li; Bao-Qing Zhang; Jian-Hao Lin; Hu Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-02-03

9.  Clinical significance of CMTM4 expression in hepatocellular carcinoma.

Authors:  Chunhua Bei; Ying Zhang; Riming Wei; Xiaonian Zhu; Zhigang Wang; Wen Zeng; Qiuyue Chen; Shengkui Tan
Journal:  Onco Targets Ther       Date:  2017-11-14       Impact factor: 4.147

10.  Identification of CMTM6 and CMTM4 as PD-L1 protein regulators.

Authors:  Riccardo Mezzadra; Chong Sun; Lucas T Jae; Raquel Gomez-Eerland; Evert de Vries; Wei Wu; Meike E W Logtenberg; Maarten Slagter; Elisa A Rozeman; Ingrid Hofland; Annegien Broeks; Hugo M Horlings; Lodewyk F A Wessels; Christian U Blank; Yanling Xiao; Albert J R Heck; Jannie Borst; Thijn R Brummelkamp; Ton N M Schumacher
Journal:  Nature       Date:  2017-08-16       Impact factor: 49.962

View more
  3 in total

1.  hsa-miR-9-5p-Mediated TSPAN9 Downregulation Is Positively Related to Both Poor Hepatocellular Carcinoma Prognosis and the Tumor Immune Infiltration.

Authors:  Shengkui Tan; Xin Song; Chenchen Zhang; Yishu Sun; Jiaxi Zhang; Zhongqi Zhang; Rongcheng Zhang; Tianmiao Zhang; Xiaonian Zhu; Hongzhuan Tan
Journal:  J Immunol Res       Date:  2022-05-12       Impact factor: 4.493

2.  CMTM Family Genes Affect Prognosis and Modulate Immunocytes Infiltration in Grade II/III Glioma Patients by Influencing the Tumor Immune Landscape and Activating Associated Immunosuppressing Pathways.

Authors:  Zeyu Wang; Jingwei Zhang; Hao Zhang; Ziyu Dai; Xisong Liang; Shuwang Li; Renjun Peng; Xun Zhang; Fangkun Liu; Zhixiong Liu; Kui Yang; Quan Cheng
Journal:  Front Cell Dev Biol       Date:  2022-02-17

3.  Identification of prognostic biomarkers in the CMTM family genes of human ovarian cancer through bioinformatics analysis and experimental verification.

Authors:  Mengjun Zhang; Jialin Wang; Haodi Yue; Lindong Zhang
Journal:  Front Genet       Date:  2022-08-30       Impact factor: 4.772

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.